Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HeraMED Ltd. ( (AU:HMD) ) has shared an update.
HeraMED Limited has entered into a pilot agreement with Lee Health, a major US healthcare provider, to deploy its HeraCARE digital maternity solution. The pilot, valued at USD $115,000, will run for three to six months and aims to validate HeraCARE’s capabilities in enhancing patient engagement and remote pregnancy monitoring. If successful, the partnership could lead to a full-scale deployment, potentially managing 2,000 pregnancies annually. This collaboration marks a significant milestone for HeraMED in the U.S. market, positioning the company for scalable expansion and aligning its commercial model with Lee Health.
More about HeraMED Ltd.
HeraMED Limited is a medical data and technology company pioneering digital maternity care solutions. The company focuses on enhancing maternity care through its clinical-grade platform, HeraCARE, which includes tools such as the HeraBEAT fetal heart rate monitors and connected blood pressure cuffs. HeraMED aims to improve patient engagement and remote monitoring in maternity care.
Average Trading Volume: 1,660,547
Technical Sentiment Signal: Buy
Current Market Cap: A$41.68M
For detailed information about HMD stock, go to TipRanks’ Stock Analysis page.